JP6004322B2 - 心血管イベントの発症リスクの検査方法 - Google Patents
心血管イベントの発症リスクの検査方法 Download PDFInfo
- Publication number
- JP6004322B2 JP6004322B2 JP2012099112A JP2012099112A JP6004322B2 JP 6004322 B2 JP6004322 B2 JP 6004322B2 JP 2012099112 A JP2012099112 A JP 2012099112A JP 2012099112 A JP2012099112 A JP 2012099112A JP 6004322 B2 JP6004322 B2 JP 6004322B2
- Authority
- JP
- Japan
- Prior art keywords
- onset
- platelets
- risk
- cardiovascular
- cli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000007211 cardiovascular event Effects 0.000 title claims description 55
- 238000012360 testing method Methods 0.000 title description 15
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 35
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 20
- 239000001115 mace Substances 0.000 claims description 20
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 201000002818 limb ischemia Diseases 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 230000002411 adverse Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 238000005259 measurement Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000007423 decrease Effects 0.000 description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000013146 percutaneous coronary intervention Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001956 EPC Anatomy 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002586 coronary angiography Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012099112A JP6004322B2 (ja) | 2012-04-24 | 2012-04-24 | 心血管イベントの発症リスクの検査方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012099112A JP6004322B2 (ja) | 2012-04-24 | 2012-04-24 | 心血管イベントの発症リスクの検査方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013228229A JP2013228229A (ja) | 2013-11-07 |
| JP2013228229A5 JP2013228229A5 (https=) | 2015-06-18 |
| JP6004322B2 true JP6004322B2 (ja) | 2016-10-05 |
Family
ID=49676005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012099112A Active JP6004322B2 (ja) | 2012-04-24 | 2012-04-24 | 心血管イベントの発症リスクの検査方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6004322B2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12590978B2 (en) | 2020-02-28 | 2026-03-31 | Phc Corporation | Method for measuring platelet activation based on soluble CLEC-2 and platelet count |
| JP7584125B2 (ja) | 2020-11-02 | 2024-11-15 | 国立大学法人千葉大学 | 心血管イベントの発症リスクの検査方法 |
| WO2025075139A1 (ja) * | 2023-10-06 | 2025-04-10 | Ｐｈｃ株式会社 | 可溶型ｃｌｅｃ－２を用いた脳心血管・腎イベントの長期的発症ハイリスク評価法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006013792D1 (de) * | 2005-02-18 | 2010-06-02 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika |
| CN102480932B (zh) * | 2009-09-01 | 2015-01-14 | 阿昂梅迪克斯公司 | 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法 |
-
2012
- 2012-04-24 JP JP2012099112A patent/JP6004322B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013228229A (ja) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Celikbilek et al. | Neutrophil to lymphocyte ratio predicts poor prognosis in ischemic cerebrovascular disease | |
| Zöller et al. | Red cell distribution width and risk for venous thromboembolism: a population-based cohort study | |
| Payancé et al. | Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis | |
| Lehner et al. | Oliguria and biomarkers of acute kidney injury: star struck lovers or strangers in the night? | |
| McCullough et al. | Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk | |
| Koziel et al. | Comparative analysis of selected scales to assess prognosis in acute pancreatitis | |
| Akdur et al. | Diagnostic utility of hematological indices in predicting adverse outcomes and severity of acute pancreatitis based on BISAP and modified Glasgow score | |
| WO2015163098A1 (ja) | 肺高血圧症の検査方法 | |
| Ergül et al. | COVID 19 disease independently predicted endothelial dysfunction measured by flow-mediated dilatation | |
| Kim et al. | Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis | |
| Ndrepepa et al. | Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention | |
| Nerkiz et al. | Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis | |
| KR20220147624A (ko) | 가용성 clec-2와 혈소판 수에 기초한 혈소판 활성화 측정 방법 | |
| JP6004322B2 (ja) | 心血管イベントの発症リスクの検査方法 | |
| McLeod et al. | Common clinical markers predict end-stage renal disease in children with obstructive uropathy | |
| Introcaso et al. | Improvement of neutrophil gelatinase-associated lipocalin sensitivity and specificity by two plasma measurements in predicting acute kidney injury after cardiac surgery | |
| Kaur et al. | Erythrocyte Sedimentation Rate: Its Determinants and Relationship with Risk Factors Involved in Ischemic Stroke | |
| Mirzaii-Dizgah et al. | Serum and saliva levels of cathepsin L in patients with acute coronary syndrome | |
| JP2007248395A (ja) | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 | |
| JP6316200B2 (ja) | サイクロフィリンａによる心血管疾患の検査方法 | |
| Sajeev et al. | High sensitivity troponin: Does the 50% delta change alter clinical outcomes in chest pain presentations to the emergency room? | |
| WO2022255348A1 (ja) | 可溶型ｃｌｅｃ２を用いた急性脳血管障害のリスク評価方法 | |
| JP7584125B2 (ja) | 心血管イベントの発症リスクの検査方法 | |
| Negreva et al. | Significant increase in C-reactive protein and serum amyloid A in the early hours of paroxysmal atrial fibrillation | |
| Ivandic et al. | High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150424 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160418 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160816 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160826 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6004322 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |